Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.

BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.

Moderna Inc.’s experimental vaccine is 94.5% effective in preventing Covid-19 based on interim data from a late-stage trial, the company said, becoming the second U.S. drugmaker to report results that far exceed expectations.

Leading pharmaceutical companies – including Moderna, Pfizer and AstraZeneca – are racing ahead to develop and distribute a Covid-19 vaccine.

Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.

The U.S. Food and Drug Administration granted Roche’s Venclexta (venetoclax) full approval in combination with azacytidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia in adults 75 years or older.

Moncef Slaoui, the head of Operation Warp Speed – the government project to push along the Covid-19 vaccine development – suggested the first Emergency Use Authorization (EUA) for a vaccine will likely be around Thanksgiving.

The U.S. government awarded $486 million to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of Covid-19 antibody treatment, a similar class of drug that was used in treating President Donald Trump.

A top U.S. health official told a U.S. Senate committee that he expects Covid-19 vaccinations to take place over many months and that most Americans could be vaccinated by July 2021 at the latest.

In anticipation of data from a Phase III vaccine candidate study potentially becoming available in October, Germany’s BioNTech acquired a manufacturing facility from Novartis to boost production capabilities for the preventative treatment for the novel coronavirus.